Both in Pharmaceuticals
Emergent Biosolutions vs Fulcrum Therapeutics
Over the past year EBS returned −41.5% and FULC returned −55.0%; their daily moves had a correlation of 0.10.
EBS −41.5% FULC −55.0%Growth of $1, one year, split-adjusted
| Metric | EBS | FULC |
|---|---|---|
| Price | $5.90 | $3.77 |
| Market cap | $302.5M | $288.0M |
| Today | −5.60% | +0.80% |
| 1 month | −15.1% | +2.2% |
| 6 months | −35.2% | −47.0% |
| Year to date | −52.3% | −66.7% |
| 1 year | −43.8% | −58.2% |
| Revenue growth (YoY) | −52.4% | — |
| Gross margin | 26.5% | — |
| Net margin | −29.7% | — |
| P/E (TTM) | — | — |
| Price / sales | 0.5× | — |
| Net cash | -$332.0M | $318.8M |
| Dividend yield | — | — |
| Volatility (60d) | 64.9% | 15.0% |
| Short % of float | 19.3% | 10.6% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).